Xcout Intel
Metsera
Metsera, Inc. is a clinical-stage biopharmaceutical company traded on the NASDAQ under the symbol MTSR, with its headquarters located in New York, New York, focusing on next-generation obesity and metabolic portfolios.
Subscribe to see Metsera’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Metsera at a glance
Metsera is a drug discovery company headquartered in United States. It has raised at least $505M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $215M in November 2024. Xcout tracks 15 named people at Metsera, including Christopher Whitten Bernard (Chief Executive Officer).
Metsera leadership
- Christopher Whitten BernardChief Executive Officer
- Clive Meanwellinitial CEO
- Whit BernardCo-Founder and current CEO
- Brian HubbardExecutive Officer
- Brian J. HubbardExecutive Officer
- Christopher J. VisioliExecutive Officer
9 more named people on record for Metsera, with roles, board committees and tenure — see the full roster →
Metsera funding rounds
At least $505M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $215M | 6 named | |
| Series A | $290M | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Metsera competitors
A few of Metsera's closest competitors — see the full list of competitors and alternatives →
Vogenx, Inc. is a clinical-stage biopharmaceutical and life science company that discovers and develops novel therapeutics to treat metabolic and gastrointestinal diseases, including post-bariatric hypoglycemia and gastroparesis. Its lead drug candidate, mizagliflozin, is an oral small molecule designed to inhibit SGLT1, reducing glucose absorption and the secretion of insulin and gastric inhibitory peptide.
Bridge Medicines LLC is a drug discovery holding company headquartered in New York, NY, that accelerates the path of therapeutic pipelines from research to patients.
Raziel Therapeutics is a clinical-stage pharmaceutical company founded in 2012 and headquartered in Rehovot, Israel. The company originated from proprietary technology and collaborates internationally on medical treatments, including fat reduction therapeutics.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Caldera Therapeutics, Inc. is a Cambridge, Massachusetts-based clinical-stage biotechnology company focused on treatments such as a bispecific inflammatory bowel disease (IBD) asset.
META Pharmaceuticals Inc. is a pioneering biotechnology company focusing on immuno-metabolism and gastrointestinal therapeutics within immunology, operating research efforts connected to JLABS in Shanghai.
Get Metsera's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Metsera in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access